FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005089506> ?p ?o ?g. }

• W2005089506 endingPage "1215" @default.
• W2005089506 startingPage "1211" @default.
• W2005089506 abstract "ObjectiveUltrasound-guided thrombin injection has become the initial treatment of choice for femoral access-related pseudoaneurysms. Patients typically undergo serial duplex examinations to assess for spontaneous resolution of small iatrogenic pseudoaneurysms (IPSAs) (<2.5 cm), or may require repeated diagnostic, therapeutic, and follow-up studies for larger IPSAs (>2.5 cm). We evaluated the impact of a revised treatment algorithm that includes primary treatment of both small (<2.5 cm) and larger pseudoaneurysms (>2.5 cm), rather than observation of smaller ones, and attempts to establish a single duplex examination via a point-of-care treatment strategy.MethodsWe reviewed 105 consecutive patients treated with ultrasound-guided thrombin injection from July 2001 through September 2004. Patient, IPSAs, characteristics, and treatment methods were examined. The number of duplex examinations per patient was evaluated over the treatment interval. Also, published cost data were used to compare primary treatment of small ISPAs vs observation with serial duplex examinations.ResultsSuccessful thrombosis occurred in 103 (98.1%) of 105 treated pseudoaneurysms. No minor or major complications occurred after thrombin injection in either small or large ISPAs, and both failures requiring operation were in the large aneurysm group. The recurrence rate for the series was 1.9% (2/105), and both recurrences were successfully treated with an additional thrombin injection. A single injection was successful in treating 43 (97.7%) of 44 small (<2.5 cm) IPSAs, and one required a second injection. Patients had an average of 3.3 duplex examinations in our first year of treatment experience, which declined to 1.5 by our third year with the institution of a point-of-care service model for all pseudoaneurysms. Based on this decreased use of duplex examination and an average treatment cohort of 35 IPSA patients per year our institution, we determined this results in a reduction of 35 hours of laboratory time and nearly 70 ultrasounds per year. Similarly for small pseudoaneurysms, a point-of-service primary treatment program rather than observation results in an estimated cost savings of $12,000, based on treating 15 small IPSAs per year.ConclusionsUltrasound-guided thrombin injection is safe and effective for the treatment of nearly all iatrogenic pseudoaneurysms. We recommend primary treatment of small pseudoaneurysms by ultrasound-guided thrombin injection rather than observation with serial duplex scans. A point-of-care treatment algorithm can result in cost savings by reducing the number of necessary duplex examinations. Ultrasound-guided thrombin injection has become the initial treatment of choice for femoral access-related pseudoaneurysms. Patients typically undergo serial duplex examinations to assess for spontaneous resolution of small iatrogenic pseudoaneurysms (IPSAs) (<2.5 cm), or may require repeated diagnostic, therapeutic, and follow-up studies for larger IPSAs (>2.5 cm). We evaluated the impact of a revised treatment algorithm that includes primary treatment of both small (<2.5 cm) and larger pseudoaneurysms (>2.5 cm), rather than observation of smaller ones, and attempts to establish a single duplex examination via a point-of-care treatment strategy. We reviewed 105 consecutive patients treated with ultrasound-guided thrombin injection from July 2001 through September 2004. Patient, IPSAs, characteristics, and treatment methods were examined. The number of duplex examinations per patient was evaluated over the treatment interval. Also, published cost data were used to compare primary treatment of small ISPAs vs observation with serial duplex examinations. Successful thrombosis occurred in 103 (98.1%) of 105 treated pseudoaneurysms. No minor or major complications occurred after thrombin injection in either small or large ISPAs, and both failures requiring operation were in the large aneurysm group. The recurrence rate for the series was 1.9% (2/105), and both recurrences were successfully treated with an additional thrombin injection. A single injection was successful in treating 43 (97.7%) of 44 small (<2.5 cm) IPSAs, and one required a second injection. Patients had an average of 3.3 duplex examinations in our first year of treatment experience, which declined to 1.5 by our third year with the institution of a point-of-care service model for all pseudoaneurysms. Based on this decreased use of duplex examination and an average treatment cohort of 35 IPSA patients per year our institution, we determined this results in a reduction of 35 hours of laboratory time and nearly 70 ultrasounds per year. Similarly for small pseudoaneurysms, a point-of-service primary treatment program rather than observation results in an estimated cost savings of $12,000, based on treating 15 small IPSAs per year. Ultrasound-guided thrombin injection is safe and effective for the treatment of nearly all iatrogenic pseudoaneurysms. We recommend primary treatment of small pseudoaneurysms by ultrasound-guided thrombin injection rather than observation with serial duplex scans. A point-of-care treatment algorithm can result in cost savings by reducing the number of necessary duplex examinations." @default.
• W2005089506 created "2016-06-24" @default.
• W2005089506 creator A5026510473 @default.
• W2005089506 creator A5036350290 @default.
• W2005089506 creator A5061921420 @default.
• W2005089506 date "2006-06-01" @default.
• W2005089506 modified "2023-09-30" @default.
• W2005089506 title "Reducing duplex examinations in patients with iatrogenic pseudoaneurysms" @default.
• W2005089506 cites W1965551643 @default.
• W2005089506 cites W1966776939 @default.
• W2005089506 cites W1980147374 @default.
• W2005089506 cites W1980429463 @default.
• W2005089506 cites W1996210639 @default.
• W2005089506 cites W1997083679 @default.
• W2005089506 cites W2015087990 @default.
• W2005089506 cites W2016113076 @default.
• W2005089506 cites W2045731490 @default.
• W2005089506 cites W2051580566 @default.
• W2005089506 cites W2061768898 @default.
• W2005089506 cites W2063654600 @default.
• W2005089506 cites W2068187932 @default.
• W2005089506 cites W2091329650 @default.
• W2005089506 cites W2097946951 @default.
• W2005089506 cites W2117923917 @default.
• W2005089506 cites W2120785361 @default.
• W2005089506 cites W2124725420 @default.
• W2005089506 cites W2136200264 @default.
• W2005089506 cites W2139486140 @default.
• W2005089506 cites W2143654108 @default.
• W2005089506 cites W2154270856 @default.
• W2005089506 cites W2154386495 @default.
• W2005089506 cites W2163094840 @default.
• W2005089506 cites W278245542 @default.
• W2005089506 cites W2790847432 @default.
• W2005089506 cites W4230128118 @default.
• W2005089506 doi "https://doi.org/10.1016/j.jvs.2006.02.044" @default.
• W2005089506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16765241" @default.
• W2005089506 hasPublicationYear "2006" @default.
• W2005089506 type Work @default.
• W2005089506 sameAs 2005089506 @default.
• W2005089506 citedByCount "17" @default.
• W2005089506 countsByYear W20050895062012 @default.
• W2005089506 countsByYear W20050895062014 @default.
• W2005089506 countsByYear W20050895062016 @default.
• W2005089506 countsByYear W20050895062017 @default.
• W2005089506 countsByYear W20050895062018 @default.
• W2005089506 countsByYear W20050895062019 @default.
• W2005089506 countsByYear W20050895062021 @default.
• W2005089506 countsByYear W20050895062022 @default.
• W2005089506 crossrefType "journal-article" @default.
• W2005089506 hasAuthorship W2005089506A5026510473 @default.
• W2005089506 hasAuthorship W2005089506A5036350290 @default.
• W2005089506 hasAuthorship W2005089506A5061921420 @default.
• W2005089506 hasBestOaLocation W20050895061 @default.
• W2005089506 hasConcept C126838900 @default.
• W2005089506 hasConcept C141071460 @default.
• W2005089506 hasConcept C2775901891 @default.
• W2005089506 hasConcept C2776098176 @default.
• W2005089506 hasConcept C2780868729 @default.
• W2005089506 hasConcept C2989005 @default.
• W2005089506 hasConcept C54355233 @default.
• W2005089506 hasConcept C552990157 @default.
• W2005089506 hasConcept C71924100 @default.
• W2005089506 hasConcept C86803240 @default.
• W2005089506 hasConcept C99611785 @default.
• W2005089506 hasConceptScore W2005089506C126838900 @default.
• W2005089506 hasConceptScore W2005089506C141071460 @default.
• W2005089506 hasConceptScore W2005089506C2775901891 @default.
• W2005089506 hasConceptScore W2005089506C2776098176 @default.
• W2005089506 hasConceptScore W2005089506C2780868729 @default.
• W2005089506 hasConceptScore W2005089506C2989005 @default.
• W2005089506 hasConceptScore W2005089506C54355233 @default.
• W2005089506 hasConceptScore W2005089506C552990157 @default.
• W2005089506 hasConceptScore W2005089506C71924100 @default.
• W2005089506 hasConceptScore W2005089506C86803240 @default.
• W2005089506 hasConceptScore W2005089506C99611785 @default.
• W2005089506 hasIssue "6" @default.
• W2005089506 hasLocation W20050895061 @default.
• W2005089506 hasLocation W20050895062 @default.
• W2005089506 hasOpenAccess W2005089506 @default.
• W2005089506 hasPrimaryLocation W20050895061 @default.
• W2005089506 hasRelatedWork W1754602832 @default.
• W2005089506 hasRelatedWork W1848118310 @default.
• W2005089506 hasRelatedWork W2046216711 @default.
• W2005089506 hasRelatedWork W2048669071 @default.
• W2005089506 hasRelatedWork W2184345946 @default.
• W2005089506 hasRelatedWork W2340945910 @default.
• W2005089506 hasRelatedWork W2377847572 @default.
• W2005089506 hasRelatedWork W2434081275 @default.
• W2005089506 hasRelatedWork W2569544679 @default.
• W2005089506 hasRelatedWork W40023729 @default.
• W2005089506 hasVolume "43" @default.
• W2005089506 isParatext "false" @default.
• W2005089506 isRetracted "false" @default.
• W2005089506 magId "2005089506" @default.
• W2005089506 workType "article" @default.